IFNL3 and Hepatic fibrosis: A number of pre-treatment host and viral factors have been associated with the outcome of BOC triple therapy.[6] These include IL28B genotype, race (black vs. non-black), liver fibrosis stage, baseline viral load, HCV-1 subtype (1a vs. 1b), body mass index (BMI), and among treatment-experienced patients, the prior response to PR.[6] In addition to baseline factors, the rate of plasma HCV RNA decline during the early on-treatment period has been identified to be strong negative predictor of outcome.